Novel treatments for familial hypercholesterolemia: Pharmacogenetics at work

Pharmacotherapy

Volumn 34, Issue 9, 2014, Pages 961-972

  Marbach, Jeffrey A ^a   McKeon, Jessica L ^a   Ross, Joyce L ^b   Duffy, Danielle ^c  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

familial hypercholesterolemia; lomitapide; mipomersen; pharmacogenetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALIROCUMAB; ANTIARRHYTHMIC AGENT; ANTIFUNGAL AGENT; APOLIPOPROTEIN B100; ATORVASTATIN; BILE ACID SEQUESTRANT; CREATINE KINASE; CYCLOSPORIN; EVOLOCUMAB; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROLIDE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MIPOMERSEN; NICOTINIC ACID; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROTEINASE INHIBITOR; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; WARFARIN; BENZIMIDAZOLE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; OLIGONUCLEOTIDE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADD ON THERAPY; ANGINA PECTORIS; APHERESIS; COGNITIVE DEFECT; CONSTIPATION; CORONARY ARTERY DISEASE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPEPSIA; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY LIVER; FLU LIKE SYNDROME; FLUSHING; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GENE; GENE MUTATION; GOUT; GRAPEFRUIT JUICE; HEADACHE; HEART PALPITATION; HETEROZYGOTE; HOMOZYGOTE; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPERURICEMIA; INJECTION SITE REACTION; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; LIVER TOXICITY; LOSS OF FUNCTION MUTATION; MAXIMUM TOLERATED DOSE; MEDICATION COMPLIANCE; MONOTHERAPY; MYALGIA; MYOPATHY; NAUSEA; PATIENT COMPLIANCE; PHARMACOGENETICS; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 GENE; REVIEW; RHINOPHARYNGITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; BLOOD; DRUG DESIGN; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; MUTATION;

ANTICHOLESTEREMIC AGENTS; BENZIMIDAZOLES; CHOLESTEROL, LDL; DRUG DESIGN; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MUTATION; OLIGONUCLEOTIDES; PHARMACOGENETICS;

EID: 84908011349     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1441     Document Type: Review

References (59)

1. Robinson JG, Goldberg AC,. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 3 (Suppl): S18-29.
2. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5 (3 Suppl): S1-8.
3. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 3 (Suppl): S9-17.
4. Ito MK, McGowan MP, Moriarty PM, National Lipid Association Expert Panel on Familial Hypercholesterolemia. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 3 (Suppl): S38-45.
5. Goldberg AC, Robinson JG, Cromwell WC, Ross JL, Ziajka PE,. Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5 (3 Suppl): S46-51.
6. Wiesbauer F, Blessberger H, Azar D, et al. Familial-combined hyperlipidaemia in very young myocardial infarction survivors (< or =40 years of age). Eur Heart J 2009; 30: 1073-9.
7. Mortality in treated heterozygous familial hypercholesterolaemia. Implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999; 142: 105-12.
8. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. Summary report. Pediatrics 2011; 128 (Suppl 5): S213-56.
9. Austin MA, Hutter CM, Zimmern RL, Humphries SE,. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004; 160: 407-20.
10. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478-90a.
11. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA,. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002; 324: 1303-6.
12. Hill J, Hayden M, Frohlich J, Pritchard P,. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb 1991; 11: 290-7.
13. Alonso R, Mata N, Castillo S, et al. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 2008; 200: 315-21.
14. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolaemia from the international FH Foundation. Int J Cardiol 2014; 171: 309-25.
15. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013; [published online November 12, 2013].
16. National Cholesterol Education Program (NECP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002; 106: 3143-421.
17. Lexi-Comp, Inc. Lexicomp Online, Lexi-Drugs Online. Hudson, OH; 2013.
18. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-39.
19. Wierzbicki AS, Humphries SE, Minhas R,; Guideline Development Group. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 2008; 337: a1095.
20. Cohen DE, Anania FA, Chalasani N,. National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97: 77C-81C.
21. Chaves FJ, Real JT, Garcia-Garcia AB, et al. Genetic diagnosis of familial hypercholesterolemia in a south European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol. J Clin Endocrinol Metab 2001; 86: 4926-32.
22. Vohl MC, Szots F, Lelievre M, et al. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Atherosclerosis 2002; 160: 361-8.
23. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64.
24. Dorr AE, Gundersen K, Schneider JC Jr, Spencer TW, Martin WB,. Colestipol hydrochloride in hypercholesterolemic patients-effect on serum cholesterol and mortality. J Chronic Dis 1978; 31: 5-14.
25. Robinson JG, Smith B, Maheshwari N, Schrott H,. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005; 46: 1855-62.
26. Ijioma N, Robinson JG,. Lipid-lowering effects of ezetimibe and simvastatin in combination. Expert Rev Cardiovasc Ther 2011; 9: 131-45.
27. Kastelein JJ, Sager PT, de Groot E, Veltri E,. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. design and rationale of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression (ENHANCE) trial. Am Heart J 2005; 149: 234-9.
28. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43.
29. Califf RM, Lokhnygina Y, Cannon CP, et al. An update on the IMProved reduction of outcomes: Vytorin efficacy international trial (IMPROVE-IT) design. Am Heart J 2010; 159: 705-9.
30. Drood JM, Zimetbaum PJ, Frishman WH,. Nicotinic acid for the treatment of hyperlipoproteinemia. J Clin Pharmacol 1991; 31: 641-50.
31. Goldberg AC,. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. Am J Cardiol 1998; 82: 35U-8U; discussion 39U-41U.
32. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55.
33. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67.
34. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34: 1279-91.
35. Mabuchi H, Koizumi J, Shimizu M, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998; 82: 1489-95.
36. Genzyme Corporation. Kynamro (mipomersen sodium) injection. Prescribing Information. Cambridge, MA; 2013.
37. Aegerion Pharmaceuticals, Inc. Juxtapid (lomitapide) capsules. Prescribing Information. Cambridge, MA; 2013.
38. Qian YW, Schmidt RJ, Zhang Y, et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptormediated endocytosis. J Lipid Res 2007; 48: 1488-98.
39. Yu RZ, Lemonidis KM, Graham MJ, et al. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 2009; 77: 910-9.
40. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114: 1729-35.
41. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010; 105: 1413-9.
42. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012; 126: 2283-92.
43. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 998-1006.
44. Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010; 51: 1057-62.
45. Clinicaltrials.gov. A study of the safety and efficacy of two different regimens of mipomersen in patients with familial hypercholesterolemia and inadequately controlled low-density lipoprotein cholesterol (FOCUS FH). Available from http://clinicaltrials.gov/ct2/show/NCT01475825?term=mipomersen&rank=3. Accessed October 30, 2013.
46. Wetterau JR, Lin MCM, Jamil H,. Microsomal triglyceride transfer protein. Biochim Biophys Acta 1997; 1345: 136-50.
47. Wetterau JR, Aggerbeck LP, Bouma ME, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992; 258: 999-1001.
48. Di Leo E, Lancellotti S, Penacchioni JY, et al. Mutations in MTP gene in abeta- and hypobeta-lipoproteinemia. Atherosclerosis 2005; 180: 311-8.
49. Wetterau JR, Gregg RE, Harrity TW, et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998; 282: 751-4.
50. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356: 148-56.
51. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ,. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008; 5: 497-505.
52. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 381: 40-6.
53. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-6.
54. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH,. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37: 161-5.
55. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH,. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-72.
56. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012; 380: 29-36.
57. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 2012; 126: 2408-17.
58. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ,. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013; 128: 2113-20.
59. Cohen JC,. Emerging LDL therapies: using human genetics to discover new therapeutic targets for plasma lipids. J Clin Lipidol 2013; 7 (3 Suppl): S1-5.